Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study (Q46293092)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study (English)

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Cytomegalovirus

0 references

1 reference

based on heuristic

inferred from title

stem cell transplantation

1 reference

based on heuristic

inferred from title

cytomegaloviral disease

1 reference

based on heuristic

inferred from title

Jo-Anne H. Young

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/18285548

Genovefa Anna Papanicolaou

object named as

Genovefa A Papanicolaou

4

0 references

14

object named as

Michael Boeckh

1 reference

Europe PubMed Central

14 January 2018

10

object named as

Nelson Chao

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

author name string

Drew J Winston

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Vinod Pullarkat

3

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Ravi Vij

5

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Estil Vance

6

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

George J Alangaden

7

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Roy F Chemaly

8

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Finn Petersen

9

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Jared Klein

11

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Kellie Sprague

12

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

Stephen A Villano

13

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

language of work or name

0 references

publication date

19 February 2008

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

111

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

11

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

5403-5410

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Definitions of cytomegalovirus infection and disease in transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

24 May 2018

Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

15 August 2018

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

15 August 2018

Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

15 August 2018

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

15 August 2018

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5726327

15 August 2018

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18285548

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2007-11-121558

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/PMC/5726327

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46293092&oldid=2103948008"